| Literature DB >> 35631272 |
Rita Nagy1,2,3, Klementina Ocskay1,2, Alex Váradi2, Mária Papp4, Zsuzsanna Vitális4, Ferenc Izbéki5, Eszter Boros2,5, László Gajdán5, Andrea Szentesi1,6, Bálint Erőss1,2,7, Péter Jenő Hegyi2,7, Áron Vincze8, Judit Bajor8, Patricia Sarlos8, Alexandra Mikó2,9, Katalin Márta1,7, Dániel Pécsi8, Andrea Párniczky1,2,3, Péter Hegyi1,2,7.
Abstract
Although excessive alcohol consumption is by far the most frequent cause of recurrent acute pancreatitis (AP) cases, specific therapy is still not well established to prevent recurrence. Generally, psychological therapy (e.g., brief intervention (BI)) is the cornerstone of cessation programs; however, it is not yet widely used in everyday practice. We conducted a post-hoc analysis of a prospectively collected database. Patients suffering from alcohol-induced AP between 2016 and 2021 received 30 min BI by a physician. Patient-reported alcohol consumption, serum gamma-glutamyl-transferase (GGT) level, and mean corpuscular volume (MCV) of red blood cells were collected on admission and at the 1-month follow-up visit to monitor patients' drinking habits. Ninety-nine patients with alcohol-induced AP were enrolled in the study (mean age: 50 ± 11, 89% male). A significant decrease was detected both in mean GGT value (294 ± 251 U/L vs. 103 ± 113 U/L, p < 0.001) and in MCV level (93.7 ± 5.3 U/L vs. 92.1 ± 5.1 U/L, p < 0.001) in patients with elevated on-admission GGT levels. Notably, 79% of the patients (78/99) reported alcohol abstinence at the 1-month control visit. Brief intervention is an effective tool to reduce alcohol consumption and to prevent recurrent AP. Longitudinal randomized clinical studies are needed to identify the adequate structure and frequency of BIs in alcohol-induced AP.Entities:
Keywords: acute pancreatitis; alcohol; brief intervention; gamma-glutamyl transferase; recurrence
Mesh:
Substances:
Year: 2022 PMID: 35631272 PMCID: PMC9144493 DOI: 10.3390/nu14102131
Source DB: PubMed Journal: Nutrients ISSN: 2072-6643 Impact factor: 6.706
Summary of patient characteristics and laboratory values.
| Unit | Overall | Elevated Admission GGT | Non-Elevated Admission GGT | |
|---|---|---|---|---|
| Patients |
| 99 | 79 | 20 |
|
| ||||
| Gender | ||||
| Male | 88 (89) | 68 (86) | 20 (100) | |
| Female | 11 (11) | 11 (14) | 0 | |
| Age (year) | Mean ± SD | 50.05 ± 11.37 | 48.84 ± 11.21 | 54.85 ± 10.96 |
| Median (IQR) | 50 (44–57) | 50 (41–56) | 54 (49–59) | |
|
| ||||
| Length of hospitalization (days) | Mean ± SD | 9.94 ± 10.53 | 9.56 ± 9.65 | 11.45 ± 13.66 |
| Median (IQR) | 6 (5–9) | 6 (5–9) | 7 (4–10) | |
| Severity | ||||
| Mild | 61 (62) | 50 (63) | 11 (55) | |
| Moderate | 28 (28) | 21 (27) | 7 (35) | |
| Severe | 8 (8) | 6 (8) | 2 (10) | |
|
| ||||
| Previous acute pancreatitis | 40 (40) | 31 (39) | 9 (45) | |
| Chronic pancreatitis | 14 (14) | 9 (11) | 5 (25) | |
| Hypertriglyceridemia | 17 (17) | 15 (20) | 2 (10) | |
| Alcohol consumption (frequency) | ||||
| None | 6 (6) | 5 (6) | 1 (5) | |
| Occasionally | 24 (24) | 14 (18) | 10 (50) | |
| Monthly | 2 (2) | 2 (3) | 0 (0) | |
| Weekly | 13 (13) | 9 (11) | 4 (20) | |
| Daily | 54 (54) | 49 (62) | 5 (25) | |
| Alcohol consumption (gram/occasion) | Mean ± SD | 81.06 ± 65.26 | 84.43 ± 69.25 | 67.55 ± 44.88 |
|
| ||||
| Admission GGT (U/L) | Mean ± SD | 364.57 ± 471.14 | 448.58 ± 493.43 | 32.7 ± 10.34 |
| Median (IQR) | 166 (64–493) | 263 (115.5–571) | 34 (28.5–39) | |
| Discharge GGT (U/L) | Mean ± SD | 255.28 ± 248.88 | 294 ± 250.75 | 36.79 ± 23.78 |
| Median (IQR) | 194 (70–399) | 229 (108–419) | 30.50 (21.25–40.25) | |
| 1-month GGT (U/L) | Mean ± SD | 88.55 ± 105.80 | 103.2 ± 113.5 | 30.65 ± 20.90 |
| Median (IQR) | 91 (87.3–94) | 53 (41–108) | 28 (18–35.25) | |
| Admission MCV (fL) | Mean ± SD | 91.45 ± 6.04 | 92.51 ± 5.69 | 97.29 ± 5.70 |
| Median (IQR) | 166 (87.8–94.65) | 92 (89–95.90) | 35 (28.5–39) | |
| Discharge MCV (fL) | Mean ± SD | 92.58 ± 5.79 | 93.73 ± 5.3 | 97.74 ± 5.34 |
| Median (IQR) | 92.5 (88.93–96.25) | 93.4 (89.95–97.03) | 87.85 (84.25–90.95) | |
| 1-month MCV (fL) | Mean ± SD | 91.02 ± 5.34 | 92.07 ± 5.10 | 86.9 ± 4.22 |
| Median (IQR) | 90.9 (87.3–94) | 91.5 (88.35–95) | 87.6 (83.92–90.33) | |
| 1-month GGT change (U/L) | Mean ± SD | 152.67 ± 195.94 | 190 ± 202.16 | 2.05 ± 17.69 |
| 1-month GGT change (U/L; %) | Mean ± SD | 40.92 ± 71.13 | 49.25 ± 74.50 | 8.04 ± 43.42 |
| 1-month MCV change (fL) | Mean ± SD | 1.50 ± 2.95 | 1.79 ± 2.93 | 0.38 ± 2.83 |
| 1-month MCV change (fL; %) | Mean ± SD | 1.53 ± 3.16 | 1.85 ± 3.12 | 0.31 ± 3.06 |
|
| ||||
| 1-month abstinence | 74 (79) | 60 (80) | 14 (70) |
GGT—gamma-glutamyltransferase; MCV—mean corpuscular volume.
Figure 1GGT and MCV values of patients in Groups E and N in different time points visualized by boxplots. E-patients with elevated on-admission GGT level (a); N-patients with non-elevated on-admission GGT level (b); GGT—gamma-glutamyltransferase; MCV—mean corpuscular volume. * p < 0.001.
Figure 2Analysis of the change in GGT and MCV levels. Figures show the change in laboratory values between discharge and the 1-month control visit. (a,b) Line chart; median ——— Q1; 3; (c,d) change in absolute value; (e,f) change in percent value. Note: in the group of patients with elevated (E) admission GGT level, discharge and 1-month values, and admission and 1-month values in the group of patients with non-elevated (N) admission GGT level, were included in the analysis. fL—femtoliter; U/L—unit/liter; E: patients with elevated admission GGT; N: patients with non-elevated admission GGT.